Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V77.1.201.BLOODJOURNAL771201PMID 1984797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components.

  1990cited by this paper
• Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components

  1990cited by this paper
• Graft-versus-leukemia reactions after bone marrow transplantation.

  1990cited by this paper
• Filtration. A method to prepare white cell‐poor platelet concentrates with optimal preservation of platelet viability

  1990cited by this paper
• Depletion of white cells from platelet concentrates with a new adsorption filter

  1989influential reference
• Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration.

  1988cited by this paper
• Prevention of refractoriness and HLA-alloimmunization using filtered blood products.

  1988influential reference
• Alloimmunization after Leukocyte‐Depleted Multiple Random Donor Platelet Transfusions

  1988influential reference
• Amount and Type of Leukocytes in ‘Leukocyte‐Free’ Red Cell and Platelet Concentrates

  1987influential reference
• Alloimmunisation to HLA Antigens following Transfusion with Leucocyte‐Poor and Purified Platelet Suspensions

  1985cited by this paper
• A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia.

  1983cited by this paper
• Alloimmunization following platelet transfusion: the absence of a dose- response relationship

  1981cited by this paper
• Alloimmunization following platelet transfusion: the absence of a dose-response relationship.

  1981cited by this paper
• Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension.

  1981cited by this paper
• Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized.

  1981cited by this paper
• Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized

  1981cited by this paper
• The Natural History of Alloimmunization to Platelets

  1978cited by this paper
• The immune response to allogeneic rat platelets; Ag‐B antigens in matrix form lacking la

  1977cited by this paper
• Antibody response in patients with acute nonlymphocytic leukemia

  1976cited by this paper
• SEROTYPING FOR HOMOTRANSPLANTATION XVIII. REFINEMENT OF MICRODROPLET LYMPHOCYTE CYTOTOXICITY TEST

  1968influential reference

• [Selection of blood products to reduce immunization before HLA-mismatched allogeneic transplantation (SFGM-TC)].

  2025cites this paper
• Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice

  2023cites this paper
• A retrospective observational study to estimate the risk of HLA alloimmunization with blood transfusion: Can the risk be reduced by leucodepletion?

  2023cites this paper
• Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in mice

  2023cites this paper
• Human leukocyte antigen alloimmunization prevention mechanisms in blood transfusion

  2022cites this paper
• Clinical Uses of Blood Components

  2021cites this paper
• The HLA System in Transfusion Medicine and Transplantation

  2021cites this paper
• Complications of Transfusion

  2021cites this paper
• Alloantibodies and Platelets

  2020cites this paper
• Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice.

  2020cites this paper
• Analysis of Plasma Products for Cellular Contaminants: Comparing Standard Preparation Methods.

  2020cites this paper
• Estimation of Proinflammatory Cytokines in Platelet Concentrates Prepared by Buffy Coat Method and Prestorage Leukofiltered/Non-Leukofiltered Platelet Rich Plasma Method – A Comparative Study

  2019cites this paper
• Pathogen reduction with riboflavin and ultraviolet light induces a quasi‐apoptotic state in blood leukocytes

  2019cites this paper
• Allogeneic major histocompatibility complex antigens are necessary and sufficient for partial tolerance induced by transfusion of pathogen reduced platelets in mice

  2019cites this paper
• Transfusion‐related immunomodulation: gamma irradiation alters the effects of leukoreduction on alloimmunization

  2019cites this paper
• Analysis of platelet‐reactive alloantibodies and evaluation of cross‐match‐compatible platelets for the management of patients with transfusion refractoriness

  2018cites this paper
• Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood

  2017cites this paper
• Maternal Anti-HLA Class I Antibodies in Connection with Pregnancy and Neonatal Thrombocytopenia – a Cause for Concern? Clinical Characteristics and Antibody Analysis of Retrospective and Prospective Populations

  2017cites this paper
• Kunstherzen (Total Artificial Heart)

  2017cites this paper
• Leucoreduction of blood components: an effective way to increase blood safety?

  2016cites this paper
• Reduced alloimmunization in mice following repeated transfusion with pathogen‐reduced platelets

  2016cites this paper
• Generation of HLA-Universal iPSC-Derived Megakaryocytes and Platelets for Survival Under Refractoriness Conditions

  2016cites this paper
• The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation

  2016cites this paper
• C1q‐binding anti‐HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants

  2016cites this paper
• A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

  2015cites this paper
• Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

  2015cites this paper
• Time Dependent Release of Interleukin-8 and Tumor Necrosis Factor-α in Platelet Concentrate

  2015cites this paper
• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

  2015cites this paper
• Besonderheiten beim Einsatz von Kunstherzen

  2015cites this paper
• Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness.

  2015cites this paper
• Universal Leukoreduction Decreases the Incidence of Febrile Nonhemolytic Transfusion Reactions to Cellular Blood Components: A 5 Year Study

  2014cites this paper
• Cross-match-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets.

  2014cites this paper
• Prevalence of platelet‐specific antibodies and efficacy of crossmatch‐compatible platelet transfusions in refractory patients

  2014cites this paper
• Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response

  2014cites this paper
• make a difference? HLA sensitization in ventricular assist device recipients: Does type of device

  2013cites this paper
• Platelet transfusion: basic aspects.

  2013cites this paper
• HLA alloimmunization in Egyptian aplastic anemia patients receiving exclusively leukoreduced blood components.

  2013cites this paper
• Quantitative assessment of erythrocytes and leucocytes in CPD- A storedblood.

  2013cites this paper
• Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants.

  2013cites this paper
• transfusion model canine prevent alloimmune platelet refractoriness and induce tolerance in a Evaluation of different methods of leukoreduction of donor platelets to

  2013cites this paper
• Introduction Transfusion of blood and blood components exposes the recipient to a wide array of alloantigens expressed on the surface of donor

  2013cites this paper
• Platelet and Granulocyte Transfusion

  2013cites this paper
• Comparison of two leukocyte reduction filters for whole blood derived platelets.

  2012cites this paper
• New approaches to preparation and storage of platelets

  2012cites this paper
• Allosensitization Rate of Male Patients Awaiting First Kidney Grafts After Leuko-Depleted Blood Transfusion

  2012cites this paper
• Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.

  2012cites this paper
• Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes.

  2011cites this paper
• Hematologic Support of the Patient with Malignancy

  2011cites this paper
• Clinical Uses of Blood Components

  2011cites this paper
• prospective study antigen-alloimmunization and refractoriness: a randomized does not prevent secondary human leukocyte Leukocyte depletion of random single-donor platelet transfusions

  2011cites this paper
• of the time of leukodepletion An animal model of allogeneic donor platelet refractoriness: the effect

  2011cites this paper
• Therapie mit Thrombozyten

  2010cites this paper
• Overview of platelet transfusion.

  2010cites this paper
• Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation

  2010cites this paper
• Leukoreduced blood components: Advantages and strategies for its implementation in developing countries

  2010cites this paper
• Zwitterionic sulfobetaine‐modified non‐woven fabric for blood filtration

  2010cites this paper
• Comparative Study of Predeposit and Bedside Leucodepletion Filters.

  2010cites this paper
• Management of allosensitized cardiac transplant candidates.

  2009cites this paper
• Medical management of radiation accidents - manual on the acute radiation syndrome

  2009cites this paper
• Berg-Loonen ' Prevention of Primary HLA Class I "

  2009cites this paper
• Leukocyte depletion for safe blood transfusion

  2009cites this paper
• Noninfectious complications of blood transfusion.

  2009cites this paper
• Preparation and Blood behaviors of Dextran-Protein Complexes

  2009cites this paper
• Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products.

  2009cites this paper
• Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation

  2009cites this paper
• Why implement universal leukoreduction?

  2008cites this paper
• Leucodepletion and disease remission in the treatment of acute leukaemia

  2008cites this paper
• GUIDELINES FOR THE TRANSFUSION OF PLATELETS

  2007cites this paper
• Management of patients refractory to platelet transfusion.

  2007cites this paper
• Chapter 39 – Transfusion to Bone Marrow or Solid Organ Transplant Recipients

  2007cites this paper
• The HLA System: Genetics, Immunology, Clinical Testing, and Clinical Implications

  2007cites this paper
• Chapter 26 – Leukocyte-Reduced Products

  2007cites this paper
• Nachweis von antigentragenden Blutzellen einschließlich Zellfragmenten in verschieden hergestellten humanen Plasmen und ihre Bewertung für die immunologische Verträglichkeit für den Plasmaaustausch bei TTP

  2006cites this paper
• Blood Transfusion as Regulator of the Immune Response

  2006cites this paper
• The clinical benefits of the leukoreduction of blood products.

  2006cites this paper
• Blood Transfusion as Regulator of the Immune Response

  2006cites this paper
• Immunology of Leucocytes, Platelets and Plasma Components

  2005cites this paper
• Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model.

  2005cites this paper
• Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.

  2004cites this paper
• Alloantibody assays and outcome of platelet transfusions

  2004cites this paper
• Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia

  2004cites this paper
• The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non‐selected haematological population of patients

  2004cites this paper
• Cyclosporine alone vs cyclosporine plus methotrexate for post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation: a randomized prospective study

  2004cites this paper
• HLA sensitization in ventricular assist device recipients: does type of device make a difference?

  2004cites this paper
• Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates.

  2004cites this paper
• Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation.

  2004cites this paper
• Management of Patients Refractory to Platelet Transfusion

  2003cites this paper
• Immune and nonimmune causes of low recovery from leukodepleted platelet transfusions: a prospective study

  2003cites this paper
• Prevention of Alloimmunization Against Platelets

  2003cites this paper
• Prophylactic platelet transfusions: which dose is the best dose? A review of the literature.

  2003cites this paper
• Applications of Meta‐Analysis in Transfusion Medicine

  2003cites this paper
• Platelet therapy

  2002cites this paper
• In Vitro Effects of Recombinant Human IL-11 on Human Malignant Lymphoma Cells

  2002cites this paper
• Altering interface detector positioning in combination with prestorage filtration to achieve a better quality of single donor platelet concentrates using the CS 3000 plus blood separator

  2002cites this paper
• Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.

  2002cites this paper
• CTLA 4 Ig Inhibits Alloantibody Responses to Repeated Blood Transfusions By

  2002cites this paper
• HLA alloimmunization in patients requiring ventricular assist device support.

  2002cites this paper
• Understanding the Effects of Different Types of White Cells on Patient's Responses to Transfusion: Immunization Versus Tolerization

  2002cites this paper
• Universal leukoreduction of cellular blood components in 2001? Yes.

  2001cites this paper
• Contributions of Meta-Analysis to Transfusion Medicine

  2001cites this paper